EP Patent

EP2120963A2 — Substituted tetracycline compounds for treatment of inflammatory skin disorders

Assigned to Paratek Pharmaceuticals Inc · Expires 2009-11-25 · 16y expired

What this patent protects

Methods and compositions for the treatment of skin disorders (e.g., acne, rosacea) are described.

USPTO Abstract

Methods and compositions for the treatment of skin disorders (e.g., acne, rosacea) are described.

Drugs covered by this patent

sarecycline-hydrochloride (SARECYCLINE HYDROCHLORIDE)

Patent Metadata

Patent number: EP2120963A2
Jurisdiction: EP
Classification: —
Expires: 2009-11-25
Drug substance claim: No
Drug product claim: No
Assignee: Paratek Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.